Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide 50 mg/kg vs 25 mg/kg in Haploidentical Stem Cell Allografts
NCT05780554Unknown
- Sponsor
- Centro de Hematología y Medicina Interna
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclophosphamide in graft-versus-host disease (GVHD), sponsored by Centro de Hematología y Medicina Interna. Primary endpoints: Acute Graft Versus Host Disease rate at 6 months and Chronic Graft Versus Host Disease rate at 18 months. Status: unknown.
02
Drugs
cyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT05780554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780554.